As supply chain vulnerabilities intensify and competition accelerates, the cost of this underutilization could risk India's competitive position.

Just weeks after announcing a deal to sell its antibiotics manufacturing in the U.S. to Neopharma, India’s Dr. Reddy’s Laboratories says it will now unload its API manufacturing business in Jeedimetla ...

According to multiple recent market analyses, the global API market is experiencing steady growth. One comprehensive forecast projects the global active pharmaceutical ingredient market to expand from ...

“Our customers, in partnership with federal and state agencies, are reshoring drug manufacturing in the U.S., the world’s largest pharmaceutical market. Local API production is vital for supply chain ...

China and India, which are the largest producers of APIs for the U.S. drug supply, also account for most of the FDA regulatory actions. Not only do quality problems at Chinese and Indian firms raise ...

EAST RUTHERFORD, N.J., Oct. 22, 2025 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), today announced a $120 million investment to expand its U.S.

HANGZHOU, ZHEJIANG, CHINA, January 16, 2026 /EINPresswire.com/ -- The pharmaceutical industry is undergoing a period of ...

Dublin, Dec. 04, 2025 (GLOBE NEWSWIRE) -- The "Active Pharmaceutical Ingredients CDMO Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, 2020-2030" report has been added to ...

The track by which API manufacturing processes are prepared for commercial use is comparable to overlapping integrative process evaluations at commercial scale. This ensures the process is ...